<SUBMISSION>
<ACCESSION-NUMBER>0000950148-02-001571
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20020619
<ITEMS>5
<ITEMS>7
<FILING-DATE>20020619
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>02682383
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v82499e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Advanced Biotherapy, Inc., Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="center"><FONT size="2"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, DC 20549</B></FONT>

<P align="center"><FONT size="2"><B>FORM 8-K</B></FONT>

<P align="center"><FONT size="2"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></FONT>

<P align="left"><FONT size="2">Date of Report (Date of earliest reported) June&nbsp;19, 2002</FONT>

<P align="center"><FONT size="2">Advanced Biotherapy, Inc.<BR>
(Exact name of registrant as specified in its chapter)</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="33%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="31%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="33%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">Delaware<BR>
(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
0-26323<BR>
(Commission<BR>
File Number)
</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">95-0402415<BR>
(IRS Employer<BR>
Identification No.)</FONT></TD>
</TR>
<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
        <TD align="center" valign="top" nowrap><FONT size="2">6355 Topanga Canyon Boulevard, Suite&nbsp;510<BR>
Woodland Hills, California<BR>
(Address of principal executive offices)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
<BR>91367<BR>
(Zip Code)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
</TABLE>
</center>
<P align="left"><FONT size="2">Registrant&#146;s telephone number, including area code (818)&nbsp;883-6716</FONT>

<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;5. OTHER EVENTS.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Signatures</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="v82499exv99w1.htm">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>








<!-- link2 "Item&nbsp;5. OTHER EVENTS." -->
<DIV align="left"><A NAME="000"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;5. OTHER EVENTS.</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant published a press release on June&nbsp;19, 2002, which announced
that the June 2002 issue of the &#147;American Journal of Ophthalmology,&#148; a
peer-reviewed scientific publication directed to ophthalmologists and visual
science specialists describing clinical investigations, clinical observations,
and clinically relevant laboratory investigations related to ophthalmology,
published the results of a company-sponsored seminal pilot study entitled
&#147;Treatment of Corneal Transplant Rejection In Humans With Anti-Interferon Gamma
Antibodies&#148; authored by Simon Skurkovich, MD, PhD, Vice President of Research &#038;
Development of Advanced Biotherapy, Inc., Alexander Kasparov, MD, PhD, Nikolai
Narbut, MD, PhD and Boris Skurkovich, MD, a Director of Advanced Biotherapy,
Inc. A copy of such press release is incorporated herein by reference and is
attached as an exhibit to this Form&nbsp;8-K.
</FONT>
<!-- link2 "Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS" -->
<DIV align="left"><A NAME="001"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</FONT>

<P align="left"><FONT size="2">(c)&nbsp;Exhibits.</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="27%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="68%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2">Designation<br>
99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Description of Exhibit<br>
Press Release, dated June&nbsp;19, 2002</FONT></TD>
</TR>
</TABLE>
</CENTER>
<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="002"></A></DIV>
<P align="center"><FONT size="2">Signatures</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
</FONT>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="45%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="50%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
ADVANCED BIOTHERAPY, INC.<br>
(Registrant)</FONT></TD>
</TR>
<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">Date: June&nbsp;19, 2002</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
By: /s/ Edmond Buccellato</FONT></TD>
</TR>
<TR>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
<HR size="1" noshade></FONT></TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Edmond Buccellato, President and CEO</FONT></TD>
</TR>
</TABLE>
</CENTER>
<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="003"></A></DIV>
<P align="center"><FONT size="2">INDEX TO EXHIBITS</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="10%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="85%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Exhibit</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><FONT size="1">Description</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD valign="top"  align="center"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Text of Press Release, dated June&nbsp;19, 2002</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">&nbsp;
</FONT>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v82499exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Advanced Biotherapy, Inc., Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P align="left"><FONT size="2">EXHIBIT 99.1</FONT>

<P align="left"><FONT size="2"><B>Advanced Biotherapy, Inc. Reports That Its Use of Antibodies to Gamma
Interferon Halts Corneal Transplant Rejection</B></FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WOODLAND HILLS, Calif.&#151; (BW HealthWire)&#151;June&nbsp;19, 2002&#151; Advanced
Biotherapy, Inc. (OTCBB: ADVB &#151; news) reported today that the June 2002 issue
of the &#147;American Journal of Ophthalmology,&#148; a peer-reviewed scientific
publication directed to ophthalmologists and visual science specialists
describing clinical investigations, clinical observations, and clinically
relevant laboratory investigations related to ophthalmology, published the
results of a company-sponsored seminal pilot study entitled &#147;Treatment of
Corneal Transplant Rejection In Humans With Anti-Interferon Gamma Antibodies&#148;
authored by Simon Skurkovich, MD, PhD, Vice President of Research &#038; Development
of Advanced Biotherapy, Inc., Alexander Kasparov, MD, PhD, Nikolai Narbut, MD,
PhD and Boris Skurkovich, MD, a Director of Advanced Biotherapy, Inc.
</FONT>
<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The article reports that, &#147;Thirteen patients (13 eyes) experiencing
corneal transplant rejection at different periods after penetrating
keratoplasty (range, 3&nbsp;months to 13&nbsp;years) were enrolled in a study performed
at the Scientific Research Institute of Eye Diseases of the Russian Academy of
Sciences, Moscow, after patient-informed consent and approval by the Department
of Reconstructive Surgery review panel were obtained. In the patients, the
corneal transplant was typically half-transparent, edematous, and cloudy.
Vision was limited to distinguishing hand movement in front of the eyes. After
standard treatment with corticosteroids, antibiotics, anti-inflammatory drugs,
and vitamins produced no improvement, (these treatments were stopped), and the
anti- interferon-gamma fragments (Fabs) were administered in a treatment course
of two to three eye drops to ensure good coverage three times a day for 7 to 10
days. In all but three patients, within 2 to 3&nbsp;days after start of treatment,
transplant transparency improved, edema dropped, and visual acuity increased.
At the end of the first week, the transplant became almost fully transparent
and inflammation of the eye disappeared. Visual acuity increased from 0.2 to
0.3. For three of the patients, two additional treatment courses given at
approximately 1-month intervals were needed to bring comparable improvement.
This condition was maintained in all 13 eyes (patients)&nbsp;through an average of 7
months of follow-up (standard deviation 2; range, 2 to 9.5). Patient G, a
52-year-old male, is an example. In 2000, this patient underwent corneal
transplantation caused by keratoconus, simultaneously with extraction of a
cataract and implantation of an artificial lens. In 2001, a transplant
rejection reaction occurred. The vision of the patient deteriorated, and the
corneal transplant became half-transparent. When standard treatments, including
daily 0.1-ml dexamethasone injections in the conjunctiva for 10&nbsp;days, had no
therapeutic effect, these treatments were stopped and anti-interferon-gamma
Fabs eyedrops were started on an outpatient basis. By day 3 of the treatment,
significant improvement in visual acuity was noted. The transplant became
almost completely transparent, and peripheral areas of the cornea became
significantly more transparent. Improvement was sustained through 9&nbsp;months of
follow-up. Anti-interferon-gamma Fabs can be considered safe and effective in
halting corneal transplant rejection after penetrating keratoplasty.&#148;
</FONT>
<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Simon Skurkovich, Vice President of Research &#038; Development stated,
&#147;These encouraging results open the door to treating, in my view, rejection of
other transplanted organs and tissue, including bone marrow, for which we have
a patent application pending, using antibodies to gamma interferon.&#148;
</FONT>
<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commenting on the publication, Mr.&nbsp;Edmond Buccellato, President and Chief
Executive Officer, stated, &#147;This study provides further confirmation regarding
our therapeutic strategy using antibodies to gamma interferon to treat a host
of autoimmune conditions. In the U.S. alone, approximately fifty
</FONT>
<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P><FONT size="2"> thousand corneal transplant surgeries are conducted annually with about
10% of those transplants rejecting. We are excited about the prospects of
furthering our studies in the U.S. for this indication, subject to necessary
regulatory approvals. In our opinion, antibodies to gamma interferon may not
only be used in specific cases of transplant rejection but possibly as a
prophylactic for all corneal transplant surgeries. We have a patent application
pending for the exclusive use of any form of antibodies to gamma interferon &#151;
including humanized and fully human, as well as other antibody types &#151; for
treating hyperimmune response in the eye.&#148;
</FONT>
<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As previously reported, the United States Patent and Trademark Office
(USPTO)&nbsp;issued U.S. Patent No.&nbsp;6,333,032 to the Company for the exclusive use
of antibodies to gamma interferon &#151; including humanized and fully human, as
well as other antibody types &#151; to treat Multiple Sclerosis, Rheumatoid
Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis (a form of
psoriasis) and Ankylosing Spondylitis. The Company also has patent
applications pending for the exclusive use of any form of antibodies to gamma
interferon for the treatment of Crohn&#146;s Disease, Psoriasis, Vitiligo and
Alopecia Areata, among other patents pending for other autoimmune diseases.
</FONT>
<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statements made in this news release, other than statements of historical
fact, are forward-looking statements and are subject to a number of
uncertainties that could cause actual results to differ materially from the
anticipated results or other expectations expressed in our forward-looking
statements. The risks and uncertainties which may affect the development,
operations and results of our business include, but are not limited to the
following: risks associated with clinical trials, the uncertainties of research
and product development programs, the uncertainties of the regulatory approval
process, the risks of competitive products, the risks of our current capital
resources, the uncertainties as to the availability of future capital and our
future capital requirements, and the risks associated with the extent and
breadth of the Company&#146;s patent portfolio. The foregoing discussion of the
effect of the patents issued and pending involves risks and uncertainties,
including but not limited to the risks that third parties may be successful in
challenging such patents; or that granted claims may be held invalid or
interpreted differently by a court of law; or that new technologies will be
developed that are superior in treating the diseases targeted by Advanced
Biotherapy, Inc. Readers are cautioned not to place reliance on these
forward-looking statements, which speak only as of the date the statements were
made. See the Company&#146;s public filings with the Securities and Exchange
Commission for further information about risks and uncertainties that may
affect the Company and the results or expectations expressed in our
forward-looking statements, including the section captioned &#147;Factors That May
Affect The Company&#148; contained in the Company&#146;s Annual Report on Form&nbsp;10-KSB for
the fiscal year ended December&nbsp;31, 2001.
</FONT>
<p>
<hr size="1" width="90" noshade  align="left">
<DIV align="left"><FONT size="2"><I>Contact:</I></FONT></DIV>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advanced Biotherapy, Inc.<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Edmond Buccellato, 818/883-6716, Ext. 2<BR>
E-mail: ed@advancedbiotherapy.com<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Website: www.advancedbiotherapy.com
</FONT>

<P align="center"><FONT size="2">&nbsp;</FONT>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
